Evidence map›Paper›PMID 41053825›Full record

ArticleMicrobiome2025

Integrated multi-omics highlights alterations of gut microbiome functions in prodromal and idiopathic Parkinson's disease.

Rémy Villette, Júlia Ortís Sunyer, Polina V Novikova, Velma T E Aho, Viacheslav A Petrov, Oskar Hickl, Susheel Bhanu Busi, Charlotte De Rudder, Benoit J Kunath, Anna Heintz-Buschart and 15 more

Erratum issuedAbstract read
In one paragraph

Article in Microbiome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Beyond bacteria: a multi-omics view of the gut-brain axis in Parkinson's disease.Frontiers in cellular and infection microbiology · 2026
    Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors.

Rémy Villette *Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Sur-Alzette, Luxembourg.
Júlia Ortís Sunyer *Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Sur-Alzette, Luxembourg.
Polina V Novikova *Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Sur-Alzette, Luxembourg.
Velma T E Aho *Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Sur-Alzette, Luxembourg.
Viacheslav A PetrovLuxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Sur-Alzette, Luxembourg.
Oskar HicklLuxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Sur-Alzette, Luxembourg.
Susheel Bhanu BusiLuxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Sur-Alzette, Luxembourg.
Charlotte De RudderLuxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Sur-Alzette, Luxembourg.
Benoit J KunathLuxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Sur-Alzette, Luxembourg.
Anna Heintz-BuschartLuxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Sur-Alzette, Luxembourg.
Jean-Pierre TrezziLuxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Sur-Alzette, Luxembourg.
Rashi HalderLuxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Sur-Alzette, Luxembourg.
Christian JägerLuxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Sur-Alzette, Luxembourg.
Laura A LebrunLuxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Sur-Alzette, Luxembourg.
Annegrät DaujeumontLuxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Sur-Alzette, Luxembourg.
Sebastian SchadeParacelsus-Elena-Klinik, Kassel, Germany.
Annette JanzenDepartment of Neurology, Philipps-University Marburg, Marburg, Germany.
Nico JehmlichDepartment of Molecular Toxicology, Helmholtz-Centre for Environmental Research GmbH - UFZ, Leipzig, Germany.
Martin von BergenDepartment of Molecular Toxicology, Helmholtz-Centre for Environmental Research GmbH - UFZ, Leipzig, Germany.
Cédric C LacznyLuxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Sur-Alzette, Luxembourg.
Patrick MayLuxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Sur-Alzette, Luxembourg.
Claudia TrenkwalderDepartment of Neurosurgery, University Medical Center Göttingen, Göttingen, Germany.
Wolfgang OertelDepartment of Neurology, Philipps-University Marburg, Marburg, Germany.
Brit MollenhauerDepartment of Neurology, University Medical Center Göttingen, Göttingen, Germany.
Paul WilmesLuxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Sur-Alzette, Luxembourg. paul.wilmes@uni.lu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundParkinson's disease (PD) is associated with gut microbiome shifts. These shifts are mainly described at taxonomic level, but the functional consequences remain unclear. To obtain insight into the functional disruptions of the gut microbiome in PD, we used an integrated multi-omics approach, comparing gut microbiomes of individuals with PD, prodromal PD, and healthy controls.

resultsMeta-metabolomics, the most discriminatory and robust omics level, was selected to Guide the analysis. We identified 11 metabolites that were differentially abundant between the groups, among which β-glutamate was increased in PD and prodromal PD, and correlated with the transcriptional activities of Methanobrevibacter smithii and Clostridium spp. We identified decreases in transcripts, but not in gene abundances, related to glutamate metabolism, bile acids biosynthesis, chemotaxis, and flagellar assembly in PD, particularly in keystone genera such as Roseburia, Agathobacter, and Blautia. Our findings, integrated into the Expobiome map, reveal multifactorial microbiome alterations which converge with PD pathways.

conclusionOur study highlights the apparent disruption of microbial gene expression in PD, particularly in genes associated to mobility. Moreover, we showcase the importance of investigating the gut microbiome's functional dimensions to better resolve microbiome-host interactions in health and disease.

Indexed as

BacteriaGastrointestinal MicrobiomeMetabolomicsParkinson DiseaseAgedFecesFemaleHumansMaleMetabolomeMiddle AgedMultiomicsProdromal SymptomsBile acidsFlagellaGene expressionGut microbiomeMulti-omicsParkinson’s disease

Identifiers

PMID41053825
PMCPMC12502400

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.